Compare Inovio Pharmaceuticals Inc (INO) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Impinj Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while Impinj Inc trades at $177.19 (market cap $5.32B). The key difference: Impinj Inc is far larger — about 67.7× Inovio Pharmaceuticals Inc's market cap, and Impinj Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | PI | |
|---|---|---|
Market Cap | $78.55M | $5.32B |
Sector | Health | Technology |
52-Week High | $2.87 | $241.91 |
52-Week Low | $0.66 | $91.34 |
Enterprise Value | $49.56M | $5.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Impinj (PI) trades at $177.33, up 0.61% with a bullish technical outlook supported by moving averages and strong institutional interest. The company reported record Q2 2026 revenue and earnings beats, though profitability remains negative with -7.26% net margins. Recent news highlights institutional accumulation and positive earnings momentum despite insider selling activity.
The stock offers growth potential from RFID market leadership and strong quarterly performance, but faces risks from negative profitability, high valuation multiples, and concentrated revenue streams. Analyst consensus remains strongly bullish with a $186 price target, representing 4.9% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
